Cell and Gene Therapy

Loom of Patent Expiry leads Bristol-Myers Squibb to nix 58 marketing jobs Bristol-Myers Squibb will soon bid farewell to its exclusive lock on a pair of HIV drugs—and, as a result, 58 workers will bid farewell to their jobs. The company is making changes to their HIV portfolio businessin anticipation of end-of-year generic competition, and those changes include nixing all commercial backing for the HIV lineup in the U.S. Effective Oct. 6. Six of the employees work at Bristol-Myers’ Princeton Pike facility, and the other 52 are remote workers scattered across the country who report to managers located at Princeton Pike. The two meds each brought in big bucks last year, ...